Attendee search 

Present Value specialise in acquisition, divestment, licensing, partnering and strategy in life science. Our experience is purely pharmaceutical and anyone who works on your prospective project will have worked in the industry for some time.  Of course, we also benefit hugely from an excellent network that has been built organically through our project work (a recent project may saw us liaising with more than one hundred companies across Europe as an example).

Recently celebrating over 10 years of success for our clients, Present Value was founded back in 2007. You can get a flavour of the types of projects and transactions we work on by looking at some of the cases histories on our website.  Alternatively, please see below for a synopsis...

1. Acquire - We will find you new targets:

·         It is difficult to find businesses or assets to acquire, especially the right shape and size for your business. We have a structured way of hunting for deals and maintain a database of potential sellers. We can be your extra set of eyes and ears out there.

2. Divest - You deserve the right value for your asset or company:

·         We would not call a company Present Value if we did not understand the equation. It is not just about an equation, it is about a thorough understanding of what drives the value in your business. We have developed an efficient process to gain you best value for your asset. You get on with running your business while we organise all the relevant documentation and deal with potential buyers.

3. Licensing - Take the essential route to pharmaceutical licensing:

·         We spend a lot of time at the pharmaceutical industry’s partnering meetings and have a good idea of what each company is looking for or what they might be offering. We tend to stick to branded innovative licensing.

4. Consulting - Expert analysis on every aspect in business of Life Science:

·         If you are struggling with something or looking to get some fresh ideas, we work on all sorts of business development projects and strategies. They are always about unlocking extra value and getting the best out of your assets.

All our projects are bespoke to you and should your project require more specialist corporate finance, regulatory or legal input we can cover that too and tend to put together a bespoke team of competent individuals or complimentary firms.

Our past and current clients range from individual entrepreneurs, family firms, country subsidiaries and global entities.  We are proud of our track record of repeat and continuing business from a number of our clients, many of whom have taken us with them when they move to a new company.

If you would like to have a chat about how we can help, please call on +44 (0) 1892 825663 or if you at any PLG, EMIG, Bio Europe event, we’re likely to be there too.

We’re generally useful to know and we look forward to hearing from you.

Both Andrew Dean and Adam Minshall are available for meetings in Montreux.  Alternatively, why not just find either of us for an informal chat.

With 80 years of experience, Italfarmaco develops activities in the entire value chain of pharmaceutical and chemical industry, from manufacturing to commercialization and development.

Group Headquarters are located Milan, with direct presence in 26 countries across Europe, America, Asia and MENA

We are interested in licensing-in, product acquisition, M&A and licensing out

Angelini, established in 1919, is a privately-held, family owned international Group with a consolidated revenue for 2017 of € 1,7 billion. Pharma represents the core business of Angelini family, with a revenue of € 851 million.

Headquartered in Rome, Italy, Angelini Pharma is a fully integrated company from R&D to Commercial and operates directly in more than twenty countries, including Italy, Spain, Central Eastern European countries, Russia and Turkey.

Angelini focuses his research and commercial activities mainly on Pain, Infectious Diseases and Central Nervous System.

R&D Department has full development capabilities from discovery to clinical and it has currently development programs ongoing in all the core therapeutic areas. Amongst others, R&D synthetized and developed both Benzydamine- for treatment of Sore throat- and Trazodone- for treatment of Major Depression- two molecules worldwide present either through Angelini direct operations or licensing-out deals.

Angelini field force- that counts more than 1.100 professionals - promotes a wide range of products coming both from internal development and licensing agreements, targeting and detailing a number of Healthcare professionals ranging from Pharmacist and General Practitioner to specialty care physicians of Psychiatry, Neurology, Infectious Disease, Pain, Oncology, Paediatric and Gynaecology.

Angelini represents a partner of choice for new product licenses for its territories with ready-to-use capabilities in terms of Regulatory, Market Access, Medical and Commercial. A list of partners of Angelini includes amongst others Helsinn, Incyte, Allergan, Dainippon Sunovion, Gilead, Zambon, Fidia, Almirall and Expanscience. Business Development is looking for innovative products in late stage development in Pain, Infectious Disease and CNS with companies interested in long-term partnership. M&A and Divestment opportunities are also in the scope when there’s a fitting to Angelini focus and Geography.

Hovione has over 57 years of experience as a CDMO and is currently a fully integrated supplier offering from drug substance to drug product intermediate to drug product. With four FDA inspected sites in the US, China, Ireland, and Portugal, and development laboratories in Lisbon and New Jersey, the company provides branded pharmaceutical customers services for the development and compliant manufacture of innovative drugs and is able to support highly potent compounds. For generic pharmaceutical customers the company offers niche off-patent API products. In the inhalation area Hovione is the only independent company offering a complete range of services. Hovione  has recently created a pharmaceutical Licensing Department identifying new  indications for existing molecules. We look forward to discussing your requirements at Montreaux. Please visit  visit http://www.hovione.com.